Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$27,000.00

Development of an oral reovirus vaccine for neuroblastoma

EF 2024-25

Résumé
Neuroblastoma (NB) is one of the most common pediatric cancers with a very high recurrence rate. Up to half of patients diagnosed with high-risk NB relapse following surgery and chemotherapy, often with poor survival rates. It is evident current treatment methods are not effective against relapse. Reovirus (respiratory enteric orphan virus) is non-pathogenic and is a well characterized oncolytic virus, having been administered to cancer patients for its ability to replicate in and kill cancer cells. Reovirus natural infectious route is through the oral-fecal system, despite this, it has never been tested as an orally administered cancer vaccine. Compared to conventional treatments which can be toxic and physically exhausting to patients, the mechanism of action of a cancer vaccine is to prime immune cells to recognize cold tumours and launch a robust anti-tumour response. Our lab has demonstrated that reovirus can be genetically modified to express an immunogenic epitope from the common antigen ovalbumin (OVA). Upon oral administration of reovirus-OVA, our results have shown a reduction in tumour burden in a metastatic melanoma model. These results underscore the ability of a reovirus vaccine to act both curatively and prophylactically to treat and prevent cancer recurrence. Building upon these results to assess tumour specific epitopes in a pediatric cancer model is this project goal. I hypothesize that orally delivered reovirus expressing NB epitopes will elicit an anti-tumour immune response in mice to suppress tumour growth and prevent recurrence. This project aims to target cancer recurrence through a non-invasive oral reovirus vaccine to act curatively and prophylactically.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529900
Name
Walia Eknoor
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of an oral reovirus vaccine for neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Neuroblastoma; Oncolytic Vaccines; Oncolytic Virus; Reovirus
Abstract
Neuroblastoma (NB) is one of the most common pediatric cancers with a very high recurrence rate. Up to half of patients diagnosed with high-risk NB relapse following surgery and chemotherapy, often with poor survival rates. It is evident current treatment methods are not effective against relapse. Reovirus (respiratory enteric orphan virus) is non-pathogenic and is a well characterized oncolytic virus, having been administered to cancer patients for its ability to replicate in and kill cancer cells. Reovirus natural infectious route is through the oral-fecal system, despite this, it has never been tested as an orally administered cancer vaccine. Compared to conventional treatments which can be toxic and physically exhausting to patients, the mechanism of action of a cancer vaccine is to prime immune cells to recognize cold tumours and launch a robust anti-tumour response. Our lab has demonstrated that reovirus can be genetically modified to express an immunogenic epitope from the common antigen ovalbumin (OVA). Upon oral administration of reovirus-OVA, our results have shown a reduction in tumour burden in a metastatic melanoma model. These results underscore the ability of a reovirus vaccine to act both curatively and prophylactically to treat and prevent cancer recurrence. Building upon these results to assess tumour specific epitopes in a pediatric cancer model is this project goal. I hypothesize that orally delivered reovirus expressing NB epitopes will elicit an anti-tumour immune response in mice to suppress tumour growth and prevent recurrence. This project aims to target cancer recurrence through a non-invasive oral reovirus vaccine to act curatively and prophylactically.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Walia, Eknoor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~